Unique numbers and capabilities

PreciseInhale: Milligrams, not grams. Months, not years. Maximum versatility.

PreciseInhale, our patented aerosol generation R&D platform is a paradigm shift in inhalation R&D technology. Its unique capabilities accelerate drug development and research timelines in the inhalation field. Developed over 10 years in collaboration with big pharma companies such as Astra Zeneca and GSK it is a complete, compact inhalation lab on the benchtop.

Milligrams, not grams

PreciseInhale typically uses between 50-100 mg of expensive test substance for a full PK study. Able to aerosolize even challenging dry powders efficiently, it achieves an even distribution in the lungs from less than 100 mg of costly test substance.

Months, not years

With its precision dosing and unique one-animal-at-a-time system, PreciseInhale delivers data with typical standard deviation of <10%. Inhaled drug developers can take key ‘go / no go’ strategic decisions on projects more confidently, and at an earlier stage of development.

Maximum versatility

PreciseInhale is multi-module. It delivers the right exposure for every stage of R&D from cell cultures and rodents up to dogs and humans. A complete inhalation lab on your benchtop, it is the only inhalation R&D platform that can generate aerosols from a range of sources – dry powders, nebulized compounds, Dry Powder Inhalers (DPIs) or pressurized Metered Dose Inhalers (pMDIs), generating highly relevant comparative data from marketed products.